Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
HER2- Metastatic Breast Cancer
.
Show all posts
Showing posts with label
HER2- Metastatic Breast Cancer
.
Show all posts
Wednesday, June 5, 2019
FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
›
In continuation of my update on palbociclib Pfizer announced that the U.S. Food and Drug Administration (FDA) approved a suppleme...
Friday, May 27, 2016
Pfizer Receives Expanded FDA Approval For Ibrance (palbociclib) In HR , HER2- Metastatic Breast Cancer
›
Palbociclib (codenamed PD-0332991 , trade name Ibrance ) Pfizer Inc., announced that the U.S. Food and Drug Administration (...
Friday, May 13, 2016
Pfizer Receives Expanded FDA Approval For Ibrance (palbociclib) In HR , HER2- Metastatic Breast Cancer
›
In continuation of my updates on palbociclib Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) h...
Wednesday, May 11, 2016
Pfizer Receives Expanded FDA Approval For Ibrance (palbociclib) In HR , HER2- Metastatic Breast Cancer
›
In continuation of my updates on palbociclib Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) h...
›
Home
View web version